Aphria Enters Polish Market Via Arrangement With ODI Pharma AB
It appears that Aphria Inc (TSX: APHA) (NASDAQ: APHA) is expanding its distribution to Poland. It was announced jointly with ODI Pharma AB this morning that the two firms have entered into a supply agreement for distribution to the country.
Under the terms of the supply agreement, which was entered into via CC Pharma, ODI will have the exclusive right to sell cobranded products under the ODI and Aphria brand names within Poland. While details are slim on specifics, what is known is that the supply agreement is for a period of five years, with annual minimums of 1,200 kilograms of medical cannabis product.
In total, the agreement is for 6,000 kilograms of medical cannabis over the five year term. CC Pharma will also support ODI in securing regulatory approval for import and sale of the co-branded products.
Monetary values of the transaction were not provided.
ODI Pharma is a producer and reseller of finished cannabis products within Europe. with the company placing an emphasis on the Polish cannabis market. The company is currently looking to become the number one provider of cannabis products in Poland.
Aphria Inc last traded at $6.32 on the Nasdaq.
Information for this briefing was found via Sedar and Aphria Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
